SELL Zydus Lifesciences Limited — Investec India
byInvestec IndiaHorizon: NA (inferred 1 year)12 Aug 2026via NDTV Profit (Live)
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.
Zydus Lifesciences shares drop 3% after Q1 earnings. Here's why Nuvama upgraded rating, hiked target
NewsEt-Markets·12 Aug · 4w ago
1 other SEBI-registered advisor has an active long-term SELL call on this stock
Advisor consensus · same horizon·12 Aug · 4w ago
Zydus Lifesciences Q1 Results: Net profit down 36% at Rs 939.8 crore
NewsEt-Markets·11 Aug · 4w ago
Zydus Pharmaceuticals USA Inc., a subsidiary of Zydus Lifesciences, has agreed to pay USD 5.9 million to settle litigation in the US District Court for the Eastern District of Pennsylvania. The settle
BSE · Company Update·5 Sept · 4d ago
From Zydus Lifesciences To Greenpanel: Check HDFC Securities' Latest Q1 Ratings, Target Prices, Outlook
NewsNdtv-Profit·12 Aug · 4w ago
Zydus Lifesciences Limited has submitted a press release regarding its unaudited financial results for the quarter ended June 30, 2026. The filing is a disclosure under SEBI regulations.
NSE · Press Release·11 Aug · 4w ago
Zydus Lifesciences Ltd has submitted a press release regarding its unaudited financial results for the quarter ended June 30, 2026, as per SEBI regulations.
BSE · Company Update·11 Aug · 4w ago
Unaudited financial results for the quarter ended on June 30, 2026
BSE · Board Meeting·11 Aug · 4w ago
India's Pharma Market Expands 10.7% On GLP-1 Launch: Zydus, Glenmark Lead Large-Cap Growth
NewsNdtv-Profit·9 Sept · today
Long-term trend bullish — 200-day average rising over the past quarter
Technicals · trend·8 Sept · yesterday
Zydus Lifesciences announced positive topline results from the completed EVIDENCES-X Phase II(b) clinical trial of Saroglitazar Mg for MASH.
BSE · Company Update·31 Aug · 1w ago
Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating. Here's Why
NewsNdtv-Profit·27 Aug · 2w ago
Zydus Lifesciences Shares Tick Higher On USFDA Nod For Ascorbic Aid Injection
NewsNdtv-Profit·21 Aug · 3w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.